Hi {{lead.First Name:default=edit me}},

You know that human biospecimens represent the best research model, but accessing the right human samples can be challenging. Fortunately, Lilly’s pipeline matches well with Sanguine’s network of highly characterized, recallable patient donors, so you can choose I/E criteria and timely receive the right samples, including PBMCs and leukopaks. Sanguine’s nationwide donor network includes (search the database):

  • >13,000 donors with autoimmune indications, our most diverse patient group
  • >2,000 donors with metabolic diseases, including diabetes (type I & II) and CKD
  • >1,500 donors with neurological disorders, including Alzheimer’s and Parkinson’s

Lilly’s respect for people core value synergizes with our patient-centric approach of collecting samples in-home and partnering with patient advocacy groups to accelerate discovery. Let’s discuss whether we can work together and succeed for patients.

Warm Regards,

Scott O'Donnell
Account Executive
Sanguine Bio | Massachusetts

Schedule a Meeting
| www.sanguinebio.com